Basic Information
| LncRNA/CircRNA Name | XIST |
| Synonyms | NA |
| Region | GRCh38_X:73820651-73852753 |
| Ensemble | ENSG00000229807 |
| Refseq | NR_001564 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | breast cancer |
| ICD-0-3 | C50 |
| Methods | qPCR, Luciferase reporter assay |
| Sample | blood, cell lines (MCF-12A, BT-474, BT-483, AU565, HCC1806, SK-BR-3, MDA-MB-231) |
| Expression Pattern | down-regulated |
| Function Description | The miR-20a expression was significantly up-regulated in both breast cancer samples and serum samples, and correlated with poor survival rate in breast cancer patients. LncRNAs (XIST, H19 and MALAT1) directly bound to hsa-miR-20a and were negatively correlated with hsa-miR-20a expression in breast cancer patient samples. over-expression of miR-20a and inhibition of XIST promoted breast cancer cell growth, migration and invasion in vitro, and serum miR-20a and XIST served as potential diagnostic biomarkers for breast cancer with the area under ROC curve (AUC) of 0.87 (95% CI = 0.78 to 0.97), and 0.78 (95% CI = 0.67 to 0.89) respectively. |
| Pubmed ID | 30092355 |
| Year | 2018 |
| Title | The Functional Pathway Analysis and Clinical Significance of miR-20a and Its Related lncRNAs in Breast Cancer. |
External Links
| Links for XIST | GenBank HGNC NONCODE |
| Links for breast cancer | OMIM COSMIC |